Healthcare Services company Suraksha Diagnostic announced Q3FY25 results For Q3FY25, the company reported revenue from operations of INR 595.1 million, reflecting a growth of 14.8% compared to Q3FY24. EBITDA for Q3FY25 reached INR 188.6 million, marking a 16.7% increase from Q3FY24.The EBITDA margin for Q3FY25 stood at 31.7%, up from 31.2% in the Q3FY24. PAT for Q3FY25 stood at INR 59.9 million, reflecting a growth of 31.9% YoY. The PAT margin for Q3FY25 was 10.1%, compared to 8.8% in the Q3FY24. Ritu Mittal, Joint Managing Director & CEO said: We reported strong performance during the third quarter and nine months ended FY25 and remain poised to continue to deliver strong revenue growth and margins over the long term. Given the expectations, our performance was curtailed in current quarter due to external factors such as the doctors’ strike, which had a lingering adverse impact on our operations during the quarter. The seasonal weakness during the third quarter reflected in a pull-back in our top-line and EBITDA levels, when comparing on a quarter-on-quarter basis. However, margins were partially supported on a YoY basis on the back of efficient cost control measures. We remain steadfast in our focus on internal growth through the addition of new centers as well as exploring inorganic growth opportunities. These focus areas position us well to further strengthen our dominance in the Eastern region of India. We expect to continue to leverage our strong presence to drive a pick-up in the business and margins going forward. Result PDF